Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
| (Q3)Dec 31, 2025 | (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -177.16%-68.86K | -683.66%-224.46K | -50.35%-42.95K | -120.79%-324.19K | -3,899.26%-356.22K | 268.72%89.24K | -245.72%-28.64K | 76.77%-28.57K | 71.29%-146.83K | 113.63%9.38K |
| Net income from continuing operations | -33.83%-230.69K | -28.83%-326.65K | -23.68%-229.79K | 20.32%-1M | 46.33%-393.21K | 17.76%-172.37K | -52.61%-253.55K | -21.57%-185.79K | 21.02%-1.26M | 16.37%-732.6K |
| Operating gains losses | 45.92%-11.81K | -169.38%-14.17K | 26.87%25.44K | -923.61%-1.92K | -37.31%-20.55K | -243.47%-21.84K | 240.14%20.42K | 37.83%20.05K | -98.65%233 | -4,281.01%-14.97K |
| Depreciation and amortization | --0 | --0 | --0 | -76.80%14.91K | --0 | --0 | -63.38%5.96K | -45.14%8.95K | -9.74%64.28K | -29.57%15.74K |
| Asset impairment expenditure | ---- | ---- | ---- | -104.92%-10.08K | ---- | ---- | ---- | ---- | 519.18%204.76K | ---- |
| Unrealized gains and losses of investment securities | --0 | ---- | ---- | --149.93K | --51.64K | --14.73K | ---- | ---- | --0 | --0 |
| Remuneration paid in stock | -120.29%-1.43K | -81.80%1.29K | -60.50%2.87K | -26.37%16.21K | -175.10%-5.19K | 149.00%7.07K | -29.21%7.07K | 218.46%7.26K | -96.42%22.02K | -98.88%6.91K |
| Other non cashItems | 1,529.72%76.68K | 238.46%64.02K | 213.36%32.33K | -578.95%-143.29K | -289.66%-63.18K | -115.80%-5.36K | -201.85%-46.24K | 65.53%-28.52K | 245.59%29.92K | 312.21%33.31K |
| Change In working capital | -71.46%76.21K | -26.12%113.87K | -15.57%126.2K | -17.42%654.97K | -83.00%84.34K | 200.79%267.02K | 19.76%154.13K | 88.15%149.48K | 132.88%793.15K | 225.50%496.23K |
| -Change in receivables | 32.45%-2.94K | -107.52%-1.89K | 83.75%-736 | 2,003.29%27.22K | -83.47%11.01K | -119.08%-4.35K | 131.36%25.09K | -132.37%-4.53K | 94.47%-1.43K | 764.41%66.59K |
| -Change in inventory | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---13.36K | ---- |
| -Change in prepaid assets | -733.73%-9.66K | -22.25%1.46K | -85.72%1.44K | -0.21%10.33K | 65.10%-3.16K | -6.67%1.52K | -76.85%1.87K | 4.20%10.09K | -79.17%10.35K | -201.25%-9.06K |
| -Change in payables and accrued expense | -67.09%88.8K | -10.11%114.31K | -12.80%125.5K | -22.59%617.42K | -83.08%76.5K | 202.77%269.84K | -36.62%127.17K | 158.06%143.92K | 151.78%797.59K | 194.46%452.06K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -202.03%-91.05K | -464.31%-161.64K | -50.35%-42.95K | -120.79%-324.19K | -3,899.67%-356.22K | 268.72%89.24K | -245.73%-28.64K | 76.77%-28.57K | 71.29%-146.83K | 113.63%9.38K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 74.33%-57.78K | -136.27%-38.37K | 88.04%-5.42K | 174.33%94.63K | 371.67%259.28K | -1,248.50%-225.13K | 604.94%105.8K | -48.54%-45.32K | 73.91%-127.3K | 26.36%-95.44K |
| Net PPE purchase and sale | 76.12%-57.78K | -374.71%-38.37K | 88.04%-5.42K | 88.96%-14.05K | 371.67%259.28K | -1,334.46%-241.98K | 166.67%13.97K | -48.54%-45.32K | 73.91%-127.3K | 26.36%-95.44K |
| Net investment purchase and sale | --0 | ---- | ---- | --108.68K | --0 | --16.85K | ---- | ---- | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 74.33%-57.78K | -136.27%-38.37K | 88.04%-5.42K | 174.33%94.63K | 371.67%259.28K | -1,248.50%-225.13K | 604.94%105.8K | -48.54%-45.32K | 73.91%-127.3K | 26.36%-95.44K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -102.49%-4.23K | 14,640.07%247.47K | -100.56%-600 | 51.49%414.34K | 1,745.62%139.1K | 18.97%169.74K | 72.35%-1.7K | -26.30%107.2K | -61.22%273.52K | -115.88%-8.45K |
| Net issuance payments of debt | -102.49%-4.23K | 14,640.07%247.47K | -100.56%-600 | 235.45%414.34K | 1,745.62%139.1K | 297.80%169.74K | 72.35%-1.7K | 12.30%107.2K | 1,531.66%123.52K | -114.70%-8.45K |
| Net common stock issuance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | --150K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -102.49%-4.23K | 14,640.07%247.47K | -100.56%-600 | 51.49%414.34K | 1,744.53%139.01K | 19.04%169.83K | 72.35%-1.7K | -26.30%107.2K | -61.22%273.52K | -115.88%-8.45K |
| Net cash flow | ||||||||||
| Beginning cash position | --174.36K | 164.01%126.48K | 1,315.42%206.64K | -4.03%14.6K | 41.59%157.3K | --0 | 389.90%47.91K | -4.03%14.6K | -95.08%15.21K | -31.26%111.1K |
| Current changes in cash | -197.31%-153.06K | 199.08%47.46K | -247.03%-48.97K | 30,242.74%184.78K | 144.51%42.07K | 43.82%157.3K | -542.79%-47.91K | 515.16%33.31K | 99.79%-613 | 34.89%-94.52K |
| Effect of exchange rate changes | --1.59K | --418 | ---31.19K | --7.26K | 466.08%7.26K | --0 | --0 | --0 | --0 | ---1.98K |
| End cash Position | -85.45%22.89K | --174.36K | 164.01%126.48K | 1,315.42%206.64K | 1,315.42%206.64K | 41.59%157.3K | --0 | 389.90%47.91K | -4.03%14.6K | -4.03%14.6K |
| Free cash from | 2.56%-148.83K | -1,262.92%-200.01K | 34.53%-48.37K | -41.63%-388.24K | -70.73%-146.94K | -358.81%-152.74K | -1,031.46%-14.68K | 51.86%-73.89K | 72.57%-274.13K | 56.62%-86.06K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.